31.   The company developed Zenapax, an immune system drug that is used to help prevent organ rejection in patients who have had kidney transplants.

32.   The drug, rapamycin, is used in kidney transplant patients to prevent rejection by blocking cell growth.

33.   The drug, Zenapax, appears to help prevent the rejection of the transplanted organ without the side effects of the commonly used immune system suppressing agents.

34.   The FDA panel voted unanimously to recommend agency approval of the drug for use as an add-on to existing drug combinations used to prevent organ rejection.

35.   The FDA said the drug helps prevent organ rejection with little increase in side effects compared to other therapies.

36.   The FDA said the drug, originally developed by Protein Design Labs Inc., helps prevent organ rejection with fewer side effects than other therapies.

37.   The Food and Drug Administration said the drug helped prevent organ rejection with fewer side effects than other therapies.

38.   The new approach combines advances in the understanding of the biology of diabetes with new drugs for preventing rejection of transplanted tissues.

39.   To the Miami team, the most exciting finding was that they could safely prevent rejection with only one drug, not a cocktail of drugs.

40.   Together, they want to pioneer new approaches to replace long-term immunosuppresive drugs that prevent rejection after transplantion of human organs.